Ginkgo Bioworks Holdings vs Xencor
Ginkgo Bioworks Holdings is the larger business, with $170m of revenue in fiscal 2025 against $126m for Xencor (1.4 times as much). Xencor grew faster (13.7% against -25.1%). Xencor kept more of each dollar of sales as profit: a net margin of -73.2% against -183.8%.
| Latest fiscal year | Ginkgo Bioworks HoldingsDNA, 2025 | XencorXNCR, 2025 |
|---|---|---|
| Revenue | $170m | $126m |
| Revenue growth | -25.1% | 13.7% |
| Net income | −$313m | −$91.9m |
| Operating margin | — | — |
| Net margin | -183.8% | -73.2% |
| Return on equity | -51.1% | -14.0% |
| Free cash flow | −$179m | −$138m |
| Cash | $167m | $54.1m |
| Total debt | $0 | $120m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 485 | 260 |
| Market value | $671m | $2.29bn |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 24 sales | 0 buys, 18 sales |